Do we use the right criteria for determining the clinical significance of incidental prostate cancer at radical cystoprostatectomy?

References

• Damiano R, Di Lorenzo G, Cantiello F, De Sio M, Perdonà S, D'Armiento M, et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007;52:648–57.
   PubMed Web of Science ®Google Scholar
• Kefer JC, Cherullo EE, Jones JS, Gong MC, Campbell SC. Prostate-sparing cystectomy: has Pandora's box been opened? Expert Rev Anticancer Ther 2007;7:1003–14.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75.
   PubMed Web of Science ®Google Scholar
• Sruogis A, Ulys A, Smailyte G, Kardelis Z, Kulboka A, Anglickienė G, et al. Incidentally found prostate cancer and influence on overall survival after radical cystoprostatectomy. Prostate Cancer 2012; 690210. [Epub Jun 3, 2012]
   PubMedGoogle Scholar
• Gakis G, Schilling D, Bedke J, Sievert KD, Stenzl A. Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int 2010;105:468–71.
   PubMed Web of Science ®Google Scholar
• Moutzouris G, Barbatis C, Plastiras D, Mertziotis N, Katsifotis C, Presvelos V, et al. Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol 1999;33:27–30.
   PubMedGoogle Scholar
• Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, et al. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol 2005;36:646–54.
   PubMed Web of Science ®Google Scholar
• Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T. Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int 2007;99:554–8.
   PubMed Web of Science ®Google Scholar
• Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933–8.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:376–84.
   Web of Science ®Google Scholar
• Wolters T, Montironi R, Mazzucchelli R, Scarpelli M, Roobol MJ, van den Bergh RC, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121–5.
   PubMed Web of Science ®Google Scholar
• Joung JY, Yang SO, Seo HK, Kim TS, Han KS, Chung J, et al. Incidental prostate cancer detected by cystoprostatectomy in Korean men. Urology 2009;73:153–7.
   PubMed Web of Science ®Google Scholar
• Bryniarski P, Fryczkowski M, Pawlaczek P, Pliszek K, Prokopowicz G, Kaletka Z, et al. Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus coexisting prostate cancer: a research study. BMC Urol 2010;10:16.
   PubMed Web of Science ®Google Scholar
• Delongchamps NB, Mao K, Theng H, Zerbib M, Debré B, Peyromaure M, et al. Outcome of patients with fortuitous prostate cancer after radical cystoprostatectomy for bladder cancer. Eur Urol 2005;48:946–50.
   PubMed Web of Science ®Google Scholar
• Pritchett TR, Moreno J, Warner NE, Lieskovsky G, Nichols PW, Cook BA, et al. Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 1988;139:1214–16.
   PubMed Web of Science ®Google Scholar
• Abbas F, Hochberg D, Civantos F, Soloway M. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996;30:322–6.
   PubMed Web of Science ®Google Scholar
• Abdelhady M, Abusamra A, Pautler SE, Chin JL, Izawa JI. Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int 2007;99:326–9.
   PubMed Web of Science ®Google Scholar
• Kouriefs C, Fazili T, Masood S, Naseem MS, Mufti GR. Incidentally detected prostate cancer in cystoprostatectomy specimens. Urol Int 2005;75:213–16.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572–83.
   PubMed Web of Science ®Google Scholar
• Bulbul MA, Wazzan W, Farhat W, Kaouk J, Hemady K, Shamseddine AI. Feasibility of radiation and chemotherapy following cystectomy and orthotopic neobladder for invasive bladder cancer. Can J Urol 1998;5:469–71.
   PubMedGoogle Scholar
• Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735–40.
   PubMed Web of Science ®Google Scholar
• Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 2002;16:2323–37.
   PubMedGoogle Scholar
• Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288–96.
   PubMed Web of Science ®Google Scholar
• Bahrenberg G, Brauers A, Joost HG, Jakse G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 2000;275:783–8.
   PubMed Web of Science ®Google Scholar
• Zhigang Z, Wenlu S. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005;65:299–305.
   PubMed Web of Science ®Google Scholar
• Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int J Cancer 2008;122:864–70.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Ma W, Zeng G, Qi D. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. J Surg Oncol 2011;104:672–8.
   PubMed Web of Science ®Google Scholar
• Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009;41:991–5.
   PubMed Web of Science ®Google Scholar
• Study Group of Millennium Genome Project for Cancer. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730–40.
   PubMed Web of Science ®Google Scholar
• Joung JY, Lee YS, Park S, Yoon H, Lee SJ, Park WS, et al. Haplotype analysis of prostate stem cell antigen and association with prostate cancer risk. J Urol 2011;185:2112–18.
   PubMed Web of Science ®Google Scholar